z-logo
open-access-imgOpen Access
Clinical evaluation of the synbiotic Prodefen Plus® in the prevention of the antibiotic-associated diarrhoea in subjects requiring antibiotic treatment
Author(s) -
C. Barreiro Guridi,
Anja Serena,
Susana Cabrera,
Itzel Fernandez,
C. Hernandez,
Blanca Vivanco,
Mario Melguizo,
Javier Suárez-Almarza,
Concepción Nieto-Magro
Publication year - 2020
Publication title -
beneficial microbes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.114
H-Index - 40
eISSN - 1876-2891
pISSN - 1876-2883
DOI - 10.3920/bm2020.0062
Subject(s) - medicine , antibiotics , placebo , incidence (geometry) , synbiotics , population , diarrhea , antibiotic associated diarrhea , clinical trial , probiotic , clostridium difficile , physics , alternative medicine , genetics , optics , environmental health , pathology , bacteria , microbiology and biotechnology , biology
Prodefen® is a dietary food supplement formulated as a synbiotic that has shown additional benefit to the standard supportive therapy in the management of acute viral diarrhoea in children. There is scarce evidence of this synbiotic in adults. The objective of this randomised double blind placebo-controlled clinical trial was to evaluate the efficacy and safety of Prodefen Plus® in the prevention of antibiotic-associated diarrhoea (AAD) in an adult population requiring either antibiotic treatment for an oral infection or antibiotic prophylaxis for a dental surgical procedure in a dental consultation. 151 subjects were randomised to the active (synbiotic) or control arm (placebo) for 14 days. There was a significantly higher reduction in the AAD incidence, and an improvement in the stool consistency in the active group. A higher reduction in both the frequency and duration of the diarrhoea episodes in the active group was also observed, as it was an improved perception of the diarrhoea severity. Overall, the study medication was well tolerated. In conclusion, results from this study confirm the beneficial effect of the synbiotic administered as adjuvant therapy in preventing the antibiotic-associated diarrhoea.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom